http://goldbamboo.com/ Paroxysmal Choreoathetosis News from GoldBamboo.com en-us © 2005, Gold Bamboo LLC, All Rights Reserved http://goldbamboo.com/news-a211589.html Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has announced that abstracts relating to Soliris™ (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) have been published by the American Society of Hematology (ASH). [click link for full article] Thu, 14 Dec 2006 12:00 EST http://goldbamboo.com/news-a211066.html The genetic basis for a rare inherited disorder that causes severe burning pain with no warning has been pinpointed by researchers. They found that paroxysmal extreme pain disorder (PEPD) is caused by specific mutations in porelike sodium channels in peripheral nerve cells-a discovery that they said emphasizes the role of such channel disorders in inflammatory pain. [click link for full article] Tue, 12 Dec 2006 01:00 EST http://goldbamboo.com/news-a207188.html Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Biologics License Application (BLA) for Soliris(TM) (eculizumab) for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). [click link for full article] Thu, 16 Nov 2006 08:00 EST http://goldbamboo.com/news-a210672.html The genetic basis for a rare inherited disorder that causes severe burning pain with no warning has been pinpointed by researchers. They found that paroxysmal extreme pain disorder (PEPD) is caused by specific mutations in porelike sodium channels in peripheral nerve cells -- a discovery that they said emphasizes the role of such channel disorders in inflammatory pain. Such findings of abnormal function in disease also provide insights into the normal function of such channels, they said. Fri, 08 Dec 2006 04:00 EST http://goldbamboo.com/news-a199750.html A study led by Dr Peter Hillmen of the Leeds Teaching Hospitals NHS Trust, relating to an uncommon and severe haemolytic anaemia known as paroxysmal nocturnal haemoglobinuria (PNH), was published in the current issue of The New England Journal of Medicine. In the Phase III efficacy study, TRIUMPH, 87 patients were treated at 34 sites in the U.S., Canada, Europe, and Australia. [click link for full article] Sun, 24 Sep 2006 10:00 EST